Could a common mood drug slow Parkinson's? early trial hints at possibility
NCT ID NCT06099886
First seen Apr 21, 2026 · Last updated Jun 18, 2026 · Updated 14 times
Summary
This early-phase study tested whether low-dose lithium aspartate (30-45 mg/day) could slow Parkinson's disease in 15 people diagnosed within the last 4 years. Researchers measured changes in brain scans and blood markers linked to disease progression. The goal was to see if lithium is safe and worth testing in larger trials, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University at Buffalo
Williamsville, New York, 14221, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.